CASE REPORTS
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Predicting methanol clearance during hemodialysis when direct measurement is not available.

The appropriate treatment of a patient with methanol intoxication includes the use of a competitive inhibitor of alcohol dehydrogenase (ethanol, p.o. or i.v., or fomepizole) to prevent the metabolism of methanol to formaldehyde and formic acid. Where available, dialysis can be added to this therapy, since methanol is cleared well by hemodialysis. The ability to predict the time course of methanol elimination in any given patient is an essential factor in planning his or her care. Where the availability of ethanol, bicarbonate, nursing time, or dialysis machines is limited, such predictions can be used to allocate these resources quite accurately within a couple of hours of starting treatment. Even when direct measurement of methanol by gas chromatography is not readily available, its level can be estimated indirectly by a quick and easy method, using available laboratory values. The length of time necessary to clear the methanol below a toxic level can be predicted accurately. Careful interpretation of laboratory values can result in early treatment, correct treatment time, and a positive patient outcome.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app